Table of Contents
This BCC Research study provides a comprehensive analysis of biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for products and services in the biomarkers segment. Forecast provided from 2015 through 2020.
Use this report to:
Analyze products and overall industry trends for products and services
Investigate one of the most important market drivers such as the introduction of combination therapies which will contribute to market growth.
Address critically important topics for analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets and specific disease segments.
Examine the biomarkers market by product, company, geography and mechanism of action by country.
The global biomarkers market grew to $39.4 billion in 2014 from $29.3 billion in 2013.
The market is expected to grow at a five-year compound annual growth rate (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 billion in 2020.
The genomics segment is the largest sector of the market.
The segment is expected to grow from $27.9 billion in 2015 to $54.0 billion in 2020 at a CAGR of 14.1% for the period 2015-2020.
Imaging as a segment is expected to grow from $12.1 billion in 2015 to $24.4 billion in 2020 increasing at a CAGR of 15.0% for the period 2015-2020.
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for products and services in the biomarkers segment. Individual product types are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points gleaned from proprietary industry sources, company publications, industry benchmarking and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to execute effectively in order to capture profit from opportunity. The biomarkers market presents the largest of all opportunities in representative disease subsegments. This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia. This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets and specific disease segments and geographies in order to allocate resources and make effective decisions.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...
The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Increasing diagnostic applications of biomarkers, increasing ...
The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...